Guangzhou Development District and Huangpu District have now gathered 4,800 biomedical enterprises, according to a recent conference held by the district. Meanwhile, nearly 100 new drug clinical approval documents are issued annually in the district, accounting for over 90% of Guangzhou's total and ranking first in Guangdong Province for four consecutive years.

According to the conference, there were only 1,000 biomedical enterprises in the district in 2017, which has now grown to 4,800, a 3.8-fold increase.

Among them, 528 high-tech enterprises, 382 specialized and innovative enterprises, and 20 listed companies in the biomedical field have been cultivated, accounting for 74% of Guangzhou's total. The industrial output value of the biomedical industry above a designated size in the district has doubled, accounting for 57% of Guangzhou's total.

It was also reported that Huangpu District has obtained approval for the marketing of Category 1 innovative drugs for five consecutive years, with a cumulative total of nine approved drugs, accounting for 50% of the province's total.

In 2024, the number of drug registration applications in Huangpu District reached 373, more than triple that of 2018. The Huangpu District Market Supervision and Administration Bureau, in collaboration with seven departments including local customs, jointly launched Guangdong's first pilot work plan for an "import whitelist" for items used in biomedical research and development, accelerating the entry of biomedical research materials into the country.

Furthermore, Guangdong's first medical device registration guidance workstation has been established in Huangpu District, where provincial review, inspection, and examination technical platforms are concentrated. Key innovative products in the district have undergone the "priority service" channel, resulting in a 20% increase in the speed of product registration and inspection.

In terms of talent support, the district has taken the initiative nationwide to allow direct investment in seed and angel funding with a maximum loss of 100% per project, establishing 18 sub-funds in the biomedical field, with cumulative investments in 92 talent projects totaling RMB 2.506 billion.

At the same time, outstanding entrepreneurs, high-level scientific and technological talents, highly skilled talents, and backbone talents in industries with shortages have been provided with various subsidies such as housing subsidies, rental subsidies, and settlement assistance, benefiting over 1,600 high-level talents in total.

Additionally, the Sino-Singapore Guangzhou Knowledge City has cumulatively introduced more than 40 top projects, including BeiGene, Hengrui Pharmaceuticals, and Akeso, with a total investment exceeding RMB 20 billion, to build a world-class biopharmaceutical manufacturing base in Asia.